parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in renal collecting duct intercalated cells	0.75
chemistry Open Targets	compounds already reach it: daprodustat, vadadustat, roxadustat +2	1.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	8 Parkinson's papers of 355	0.71
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 6885

receipt 6893: EGLN1 in dopamine neurons, braak

power: full sample +0.06 (p 0.814, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.664, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.22, sign flips 3; without severely affected donors +0.06 (p 0.814, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EGLN1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6892: EGLN1 in microglia, braak

power: full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.573, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.33, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EGLN1 in microglia.

case closed: nothing better to follow up.

loading the receipts